Trial reportScientific reports2021
Xanthine oxidase inhibitors are associated with reduced risk of cardiovascular disease.
Trial report in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 44 citations in OpenAlex.
- The changing epidemiology of human type 2 diabetes-associated atherosclerosis: Pathophysiological mechanisms and emerging treatment possibilities.Journal of internal medicine · 2026Review
- Chronic hyperglycemia and cardiovascular dysfunction: an in-depth exploration of metabolic and cellular pathways in type 2 diabetes mellitus.Cardiovascular diabetology. Endocrinology reports · 2025Review
- High-density lipoprotein cholesterol and kidney disease progression in patients with type 2 diabetes mellitus: the Fukushima Cohort Study.BMJ open diabetes research & care · 2025Observational
- Association of red blood cell distribution width/albumin ratio with renal prognosis among patients with type 2 diabetes mellitus: A retrospective cohort study.Journal of diabetes investigation · 2025Article
- Association of hepatic steatosis with increased plasma xanthine oxidoreductase activity: MedCity21 health examination registry.Metabolism open · 2025Article
- The anti-hyperuricemia potential of bioactive natural products and extracts derived from traditional Chinese medicines: A review and perspective.Journal of pharmaceutical analysis · 2025Review
- Predictive values of four nutritional indices for adverse outcomes in patients with hypertension.Clinical and experimental nephrology · 2025Article
- Association between malnutrition and adverse renal outcomes in patients with type 2 diabetes.Journal of diabetes investigation · 2025Article
- Article
- Geriatric Nutritional Risk Index is associated with adverse outcomes in patients with hypertension: the Fukushima Cohort study.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Xanthine oxidase promotes hepatic lipid accumulation through high fat absorption by the small intestine.JHEP reports : innovation in hepatology · 2024Article
- Elevated resting heart rate is associated with mortality in patients with chronic kidney disease.Scientific reports · 2024Article
- Leucocyte Count: Inflammatory and ROS Biomarkers of ASCVD.Journal of atherosclerosis and thrombosis · 2024Article
- Impact of red blood cell distribution width-albumin ratio on prognosis of patients with CKD.Scientific reports · 2023Article
- Global status and trends in gout research from 2012 to 2021: a bibliometric and visual analysis.Clinical rheumatology · 2023Article
- Identification of the Constituents of Ethyl Acetate Fraction fromInternational journal of molecular sciences · 2023Article
- Association of polypharmacy with incidence of CKD: a retrospective cohort study.Clinical and experimental nephrology · 2023Article
- Risk Assessment of Dyslipidemias, Hyperglycemia, Hyperuricemia, and Hypertension Utilizing Self-Reported Body Silhouettes.Journal of obesity · 2023Article
- Association of serum xanthine oxidase levels with hypertension: a study on Bangladeshi adults.Scientific reports · 2022Article
- Cardiovascular protection by SGLT2 inhibitors - Do anti-inflammatory mechanisms play a role?Molecular metabolism · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As previous studies have reported finding an association between hyperuricemia and the development of cardiovascular and chronic kidney disease, hyperuricemia is thought to be an independent risk factor for hypertension and diabetic mellitus. However, we have not been able to determine whether the use of xanthine oxidase inhibitors can reduce cardiovascular disease. The present study used the longitudinal data of the Fukushima Cohort Study to investigate the relationship between the use of xanthine oxidase inhibitors and cardiovascular events in patients with cardiovascular risks. During the 3-year period between 2012 and 2014, a total of 2724 subjects were enrolled in the study and followed. A total of 2501 subjects had hypertension, diabetic mellitus, dyslipidemia, or chronic kidney disease, and were identified as having cardiovascular risks. The effects of xanthine oxidase inhibitor use on the development of cardiovascular events was evaluated in these patients using a time to event analysis. During the observational periods (median 2.7 years), the incidence of cardiovascular events was 20.7 in subjects with xanthine oxidase inhibitor and 11.2 (/1000 person-years, respectively) in those without. Although a univariate Cox regression analysis showed that the risk of cardiovascular events was significantly higher in subjects administered xanthine oxidase inhibitors (HR = 1.87, 95% CI 1.19-2.94, p = 0.007), the risk was significantly lower in subjects administered a xanthine oxidase inhibitor after adjustment for covariates (HR = 0.48, 95% CI 0.26-0.91; p = 0.024) compared to those without. Xanthine oxidase inhibitor use was associated with reduced risk of cardiovascular disease in patients with cardiovascular risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.